Daniel E. Lopes de Menezes

City:

Berkeley, California

Country:

United States

Published Applications:

Last publication date:

2025-11-27

Top Assignees for applications by Daniel E. Lopes de Menezes

The entities that hold a legal rights for patent applications filed by inventor Lopes de Menezes Daniel E.:

BRISTOL-MYERS SQUIBB COMPANY 2 Princeton, NJ United States
CELGENE QUANTICEL RESEARCH, INC. 1 San Diego, CA United States
Celgene Corporation 1 Summit, NJ United States

Recent patent applications by Lopes de Menezes Daniel E.

Daniel E. Lopes de Menezes from Berkeley, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-11-27

US20250361313A1

Chemistry; metallurgy

COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY

#2 | 2024-07-11

US20240228642A9

Chemistry; metallurgy

COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY

#3 | 2024-04-25

US20240132608A1

Chemistry; metallurgy

COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY

#4 | 2022-08-11

US20220249529A1

Human necessities

AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME

#5 | 2022-08-11

US20220249528A1

Human necessities

AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME

#6 | 2021-11-25

US20210363267A1

Chemistry; metallurgy

COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY

#7 | 2019-04-25

US20190119395A1

Chemistry; metallurgy

Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody

#8 | 2018-06-28

US20180179282A1

Chemistry; metallurgy

TREATMENT OF CANCER BY COMBINED BLOCKADE OF THE PD-1 AND CXCR4 SIGNALING PATHWAYS

InventorID:

2227120 ⎘